Brain Research, Год журнала: 2025, Номер unknown, С. 149572 - 149572
Опубликована: Март 1, 2025
Язык: Английский
Brain Research, Год журнала: 2025, Номер unknown, С. 149572 - 149572
Опубликована: Март 1, 2025
Язык: Английский
Опубликована: Фев. 27, 2025
Язык: Английский
Процитировано
0Drug Design Development and Therapy, Год журнала: 2025, Номер Volume 19, С. 1869 - 1894
Опубликована: Март 1, 2025
Polygala tenuifolia Willd. (PT) is commonly used to address cognitive impairment (CI), while Magnolia officinalis Rehd. et Wils (MO) often prescribed for gastrointestinal issues as well CI. This study seeks explore the impacts and mechanisms behind combined therapy of PT MO (PM) in treating CI, based on concept gut-brain axis. The characteristic components PT, MO, PM were identified using ultra-high performance liquid chromatography-tandem triple quadrupole mass Spectrometry (UPLC-MS/MS). A mouse model was established by D-gal induction, effects CI evaluated through behavioral tests, pathological staining, Enzyme-Linked Immunosorbent Assay (ELISA). Subsequently, network pharmacology analyze potential which improves followed validation Western blotting (WB), traditional Chinese medicine (TEM), Immunofluorescence (IF), 16S rRNA. can each alleviate decline neuropathological damage mice varying degrees, reduce expression pro-inflammatory factors (TNF-α, IL-1β, IL-6, IFN-γ, LPS) serum or hippocampal tissue, increase SOD GSH levels. Network analysis molecular experiments confirmed that upregulates tight junction s (TJs), enhances proteins cAMP pathway, inhibits p-NF-κB-p65 expression. reverses D-gal-induced gut microbiota dysbiosis, increases abundance SCFA-producing bacteria, decreases LPS-producing bacteria. alleviates reducing inflammation oxidative stress, protecting blood-brain barrier (BBB) intestinal barrier, inhibiting NF-κB activating regulating microbiota.
Язык: Английский
Процитировано
0Brain Research, Год журнала: 2025, Номер unknown, С. 149572 - 149572
Опубликована: Март 1, 2025
Язык: Английский
Процитировано
0